There are currently 1574 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
02/25/2025
Locations: University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Neoplasms
Register for Updates
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
NCT06471920
Recruiting
Physical therapy is the first line of treatment for patients with low back pain (LBP) and has been shown to be a cost-effective method for improving pain and disability in patients with chronic LBP; however, despite this effectiveness, only 7-13% of patients go on to receive physical therapy services with patients in rural communities being especially limited to do lack of provider availability, transportation, and missed work time leading to greater rates of LBP-related disability and opioid co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Chronic Low-back Pain
Register for Updates
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Wilmer Eye Institute Johns Hopkins, Baltimore, Maryland
Conditions: Glaucoma and Ocular Hypertension
Register for Updates
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Axon Clinical Research -Baltimore, Baltimore, Maryland
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acute Kidney Injury
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/24/2025
Locations: Pharmasite Research, Inc., Baltimore, Maryland
Conditions: Migraine
Register for Updates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/24/2025
Locations: The Retina Care Center (01-023), Baltimore, Maryland
Conditions: Geographic Atrophy
Register for Updates
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty
NCT06792539
Recruiting
The goal of this clinical trial is to evaluate the safety and effectiveness of the Polymotion Hip Resurfacing (PHR) System compared to total hip arthroplasty, for adults who require hip resurfacing arthroplasty due to 1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or 2) mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
02/24/2025
Locations: Sinai Hospital / LifeBridge Health, Baltimore, Maryland
Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Register for Updates
Study of M5049 in DM and PM Participants (NEPTUNIA)
NCT05650567
Recruiting
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Johns Hopkins University - Department of Medicine, Division of Rheumatology, Baltimore, Maryland
Conditions: Dermatomyositis, Polymyositis
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Participants With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site 20001-466, Baltimore, Maryland
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06362265
Recruiting
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
02/24/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Type 2 Diabetes Mellitus
Register for Updates